
AstraZeneca’s biologics arm MedImmune has struck an oncology research deal with UK biotech company Immunocore. The deal, which could be …

Bayer and Algeta have decided to avoid the usual M&A dance, opting instead to agree a business deal with little …

GlaxoSmithKline has formed a consortium of cancer research organisations in North America and Europe in a bid to accelerate the …
Bayer HealthCare is in the market to buy Norwegian oncology specialist Algeta. The German pharma group has made a bid …

Twenty years ago drugs to treat cancer were made up of chemotherapy agents which are essentially ‘blunt tools’ against the …
Boehringer Ingelheim has signed a deal with Roche subsidiary Ventana Medical Systems to develop companion diagnostic tests for Boehringer’s oncology …

Bayer HealthCare and a prestigious US academic institution have signed a five-year deal to find new oncology treatments. The German …

Astellas has appointed Claire Thom from fellow Japanese firm Takeda to be senior vice president of its global oncology development. …

Pfizer’s oncology pipeline has suffered a blow with the company abandoning a Phase III study of one of its investigational …

Roche and reinsurance firm Swiss Re have teamed up to find an innovative way into China’s healthcare market. For the …

Two-year data from Novartis’s drug Jakavi suggests that it may improve overall survival in a rare form of cancer versus …

Eli Lilly suffered a blow to its oncology programme when a new combination treatment failed to improve overall survival in …

Merck KGaA has signed a worldwide licence agreement with Danish company Symphogen which could expand its portfolio of drugs targeting …

GlaxoSmithKline has submitted its two investigational melanoma drugs to regulators in both Europe and the US. The firm is seeking …
Boehringer Ingelheim has established a translational research collaboration with the presidents and fellows of Harvard College. The aim of the …